SMS Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
SMS Pharmaceuticals is strategically transitioning towards high-value, specialized segments such as peptides, supported by a significant ₹280 crore capex program aimed at enhancing operational excellence and R&D capabilities. Management's focus on expanding its API portfolio and increasing DMF/CEP filings is expected to bolster revenue growth, although the company faces challenges from global petrochemical price volatility and regulatory complexities. Vista's financial outlook reflects moderating revenue growth, with stable margins anticipated as SMS navigates these dynamics. The company's strong balance sheet and fair valuation align with its intrinsic value, but cautious investor sentiment suggests a need for vigilance. Over the next 12-24 months, key opportunities include successful execution of brownfield expansions and commercialization of the peptide pipeline, while headwinds may arise from raw material shortages and competitive pricing pressures in the global market
Why We Like This Stock
- Strategic transition towards high-value peptides and niche molecules enhances long-term growth potential
- Significant capex program supports operational excellence and R&D investment, crucial for maintaining competitive advantage
- Strong balance sheet and fair valuation provide a solid foundation for future growth initiatives
Things To Watch Out For
- Global petrochemical price volatility poses risks to cost structures and margins
- Regulatory complexities may hinder timely execution of growth strategies and new product launches
- Cautious investor sentiment reflects concerns over moderating revenue growth and competitive pressures
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 709 | 783 | 887 | 904 | 1,019 |
| Profit Before Tax (Cr.) | 66 | 92 | 117 | 115 | 131 |
| PBT Margin | 9.3% | 11.7% | 13.2% | 12.7% | 12.8% |
| Net Profit (Cr.) | 52 | 74 | 105 | 89 | 102 |
| Earnings Per Share | 5.5 | 7.9 | 11.2 | 9.5 | 10.8 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.